Stocks Amgen Inc

More

  • *Traders see an 83 percent chance of a rate hike this week, according to the CME Group's FedWatch program. *Amgen shares were up nearly 3 percent at $162.70 in premarket trading. *Kennametal slumped 17 percent to $21.22 after it cut its 2016 profit and revenue forecasts, citing weakness and volatility in its core markets and lower oil prices.

  • Dec 14- Amgen Inc on Monday said it had reached a deal with British drugmaker GlaxoSmithKline to reacquire the sales rights to three of its products in 48 countries, including Australia as well as markets in Asia, South America and Europe. Amgen will make undisclosed milestone payments to Glaxo upon signing and the successful transition of the products back to...

  • NEW YORK, Dec 10- When health insurer Humana Inc reported worse-than-expected quarterly earnings in late 2014- including a 21 percent drop in net income- it softened the blow by immediately telling investors it would make a $500 million share repurchase. It added around two cents to the company's annual earnings per share, allowing Humana to surpass its $7.50...

  • An unmanned SpaceX Falcon 9 rocket launches from Cape Canaveral, Fla., June 28, 2015. The rocket exploded about two minutes after liftoff, destroying a cargo ship bound for the International Space Station, NASA said.

    Goldman's Robert Boroujerdi presented seven future theme predictions and their investment implications in a note to clients Wednesday.

  • Trader on the floor of the New York Stock Exchange.

    Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.

  • NEW YORK, Nov 23- U.S. drug benefit manager CVS Health said on Monday it would add Amgen Inc's Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Regeneron Pharmaceuticals and Sanofi SA. The FDA approved Repatha and Praluent, made by Regeneron and Sanofi, within weeks of each other last summer for patients...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • *Biogen to market biosimilar etanercept in Europe. LONDON, Nov 20- A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators. Worldwide sales of Amgen's Enbrel, which is marketed outside North America by...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • ZURICH, Nov 18- The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights infections in cancer patients, the Swiss group said on Wednesday. Amgen's third-quarter results last month showed sales of Neulasta up 6 percent to $1.26 billion, topping...

  • *Denmark's Genmab scores important win with new cancer drug. Shares in Genmab, already up 130 percent this year, leapt a further 12 percent on news that the drug, which was licensed to Johnson& Johnson in 2012, had won early U.S. approval, lifting Genmab's market value to around $7 billion. Still, with several analysts forecasting peak annual sales for Darzalex of $5...

  • Nov 17- Shares in Genmab jumped 11 percent on Tuesday after U.S. regulators approved an experimental blood cancer drug that the Danish biotech company licensed in 2012 to Johnson& Johnson. The U.S. Food and Drug Administration said late on Monday it had approved Darzalex for patients who had already undergone at least three prior standard treatments for...

  • Jeff DeGraaf

    Top chart analyst Jeff deGraaf explains why technical analysis should be a key part of your investing process.

  • Jeff DeGraaf

    Top chart analyst Jeff deGraaf answers investment questions from CNBC Pro subscribers and explains why a market top could be forming.

  • ORLANDO, Nov 11- An experimental cholesterol fighter being developed by Alnylam Pharmaceuticals and The Medicines Co slashed levels of bad LDL cholesterol and remained effective for six months, according to data from a small, early stage study. The drug, called ALN-PCSsc, cut LDL by more than 50 percent in the 69- subject study presented at the American Heart...

  • The American Heart Association is holding its annual scientific sessions in Orlando, Florida from Nov 7 to 11, at which the latest clinical trials and research in heart care are being presented for thousands of cardiologists and researchers, including a large government-sponsored study on the benefits of more intensive blood pressure lowering in patients...

  • BOSTON, Nov 2- Daniel Loeb's Third Point hedge fund now holds more bets on stock price declines than gains, the billionaire told investors in a letter seen by Reuters on Monday, making him one of the first hedge fund managers to outline a new strategy following a turbulent third quarter. The biggest losers during the quarter include SunEdison, Dow Chemical Co.,...

  • Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.